Theyve been around for decades, helping treat patients with type 2 diabetes and short bowel syndrome, but when it was discovered that they could also help patients with obesity, they became several household names Ozempic, Wegovy, Mounjaro, etc
Q2 2025 Snapshot Eli Lilly and Company dominates the US 57 % GLP-1 share, led by Mounjaro (tirzepatide) HCP & Zepbound (tirzepatide) HCP Novo Nordisk rules Europe 63 % value share, powered by Wegovy(semaglutide) injection 2.4 mg HCP & Ozempic APAC & Emerging Markets are the next frontier (+1113 % YoY) Together, they crossed $24 Billion in H1 2025 GLP-1 revenue proving the real blockbuster of this decade isnt oncology or immunology Its metabolic health
MMI mice received a single T3 injection at a dose of 0.25 g per gram BW were sacrificed 4 h later (MMI + T3-4h mice)
Sensitivity analyses that accounted for comorbidities and serostatus did not significantly alter the studys outcomes
Pause, assess, recalculate, and resume only when the cause is identified
6) Americans are sweet on sugar alternatives When asked what they wanted to consume less this year, the top answer among the respondents, by far, is sugar, cited by 45%
